GE HealthCare Nears $1 B Acquisition of Sofie Biosciences to Boost PET Scan Chemicals

GEHC is reportedly in advanced negotiations to buy Sofie Biosciences for about $1 billion, according to the Financial Times on September 13, 2026. Sofie Biosciences manufactures the radiopharmaceutical chemicals that make PET scans possible, a consumable that sits alongside the imaging hardware GE HealthCare already sells. Reuters carried the same story under the headline "GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports", and Seeking Alpha relayed it as well. Read the sourcing carefully: both are passing along the FT's reporting rather than confirming the talks through their own channels, and no company announcement exists. The $1 billion figure is a reported estimate attached to talks, not a signed price.

The strategic logic is straightforward even if the deal is not yet real. GE HealthCare sells imaging systems, and radiopharmaceutical tracers are the recurring consumable those systems burn through, so owning the chemistry converts one-time equipment sales into a repeatable revenue stream and gives the company more control over a supply chain that is unusually fragile: PET tracers are radioactive, decay within hours, and have to be produced close to the hospitals that use them.

For now this is a report, not a transaction, and the gap matters. Watch for a confirming statement from either party, the final price, and how it would be financed. Our own sentiment read on GEHC turned sharply positive on the news, +0.80 on the day against a +0.21 thirty-day average, even as the shares slipped 0.5% to $63.93, so the coverage has moved the conversation ahead of the tape. If the talks are confirmed, the deal could prompt competitors to pursue similar tracer-supply acquisitions; if they lapse, the story ends where it started.